Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy

Francesco Bandello, Albert Augustin, José Alain Sahel, Hicham Benhaddi, Cristina Negrini, Klaus Hieke, Gilles H. Berdeaux, José Sahel, Gilles Chaine, Michel Weber, Gabriel Quentel, Salomon Yves Cohen, Martine Mauget-Faysse, Gérard Brasseur, Jean François Korobelnik, Mustapha Benchaboune, Jean François Charlin, [No Value] Augustin, [No Value] Weinhold, [No Value] Kaut[No Value] Hyppa, [No Value] Jurgeit, Carlo Incorvaia, Ugo Menchini, [No Value] Capobianco, Francesco Boscia, [No Value] Malerba, [No Value] Setaccioli, Monica Varano, [No Value] Schiano

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Exudative ('wet') age-related macular degeneration (ARMD) is the major cause of blindness in Western developed countries. Treatments aimed at preserving vision are already available and new compounds are under development. Micro-economics information will be pivotal to justifying forthcoming investment. Objective: This study sought to investigate the costs of exudative ARMD in patients who were actively treated at ophthalmology referral centres in three European countries: France, Germany and Italy. Method: This cross-sectional observational study was conducted in France, Germany and Italy in 2004. The following data were collected: ARMD description, visual acuity (VA), and the medical and non-medical resources used for ARMD in the preceding year. The economic perspective was that of society. ANOVA for cost variables estimated the impact of ARMD per eye, adjusted for sex and age. Both hospital and ambulatory eye centres were included. Patients with exudative ARMD were stratified into four levels of severity using VA thresholds of 20/200 for the worst eye (WE) and 20/40 for the best eye (BE). The main outcome measure was medical and non-medical costs. Results: 360 patients were included (females 60%; mean age 77 years; mean interval since diagnosis 2.3 years). The two groups with the greatest difference in severity of VA loss consisted of BE ≥20/40, WE ≥20/200 (27.2% of patients) and BE

Original languageEnglish
Pages (from-to)255-268
Number of pages14
JournalDrugs and Aging
Volume25
Issue number3
Publication statusPublished - 2008

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy'. Together they form a unique fingerprint.

Cite this